Literature DB >> 23647707

Early infantile cardiomyopathy and liver disease: a multisystemic disorder caused by congenital lipodystrophy.

François-Guillaume Debray1, Christel Baguette, Stéphanie Colinet, Lionel Van Maldergem, Christine Verellen-Dumouin.   

Abstract

Congenital generalized lipodystrophy is a rare inherited multisystemic disorder associated with disturbances of adipocyte functions. We report a young boy presenting at age 1 month with liver disease and severe hypertrophic cardiomyopathy. Despite this multisystemic involvement and contrasting with a cachectic appearance, the anthropometric parameters showed marked overgrowth (+4 DS), leading to diagnosis of congenital lipodystrophy, which was confirmed by the presence of the new homozygous c.259C>T (p.Gln87*) mutation in the AGPAT2 gene. Early infantile cardiomyopathy should be considered as a specific endophenotype in Berardinelli-Seip Congenital Lipodystrophy syndrome.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23647707     DOI: 10.1016/j.ymgme.2013.04.011

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  8 in total

1.  High incidence of BSCL2 intragenic recombinational mutation in Peruvian type 2 Berardinelli-Seip syndrome.

Authors:  Nelson Purizaca-Rosillo; Takayasu Mori; Yamali Benites-Cóndor; Fuki M Hisama; George M Martin; Junko Oshima
Journal:  Am J Med Genet A       Date:  2016-11-21       Impact factor: 2.802

Review 2.  The clinical spectrum of inherited diseases involved in the synthesis and remodeling of complex lipids. A tentative overview.

Authors:  Àngels Garcia-Cazorla; Fanny Mochel; Foudil Lamari; Jean-Marie Saudubray
Journal:  J Inherit Metab Dis       Date:  2014-11-21       Impact factor: 4.982

Review 3.  The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Authors:  Rebecca J Brown; David Araujo-Vilar; Pik To Cheung; David Dunger; Abhimanyu Garg; Michelle Jack; Lucy Mungai; Elif A Oral; Nivedita Patni; Kristina I Rother; Julia von Schnurbein; Ekaterina Sorkina; Takara Stanley; Corinne Vigouroux; Martin Wabitsch; Rachel Williams; Tohru Yorifuji
Journal:  J Clin Endocrinol Metab       Date:  2016-10-06       Impact factor: 5.958

4.  Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy.

Authors:  Josivan Gomes Lima; Lucia Helena C Nobrega; Natalia Nobrega Lima; Marcel Catão Ferreira Dos Santos; Pedro Henrique Dantas Silva; Maria de Fatima P Baracho; Debora Nobrega Lima; Julliane Tamara Araújo de Melo Campos; Leonardo Capistrano Ferreira; Francisco Paulo Freire Neto; Carolina de O Mendes-Aguiar; Selma Maria B Jeronimo
Journal:  PLoS One       Date:  2018-06-08       Impact factor: 3.240

5.  Genotype-phenotype correlations of Berardinelli-Seip congenital lipodystrophy and novel candidate genes prediction.

Authors:  Meng Ren; Jingru Shi; Jinmeng Jia; Yongli Guo; Xin Ni; Tieliu Shi
Journal:  Orphanet J Rare Dis       Date:  2020-04-29       Impact factor: 4.123

6.  Clinical and Mutational Features of Three Chinese Children with Congenital Generalized Lipodystrophy.

Authors:  Xueying Su; Ruizhu Lin; Yonglan Huang; Huiying Sheng; Xiaofei Li; Tzer Hwu Ting; Li Liu; Xiuzhen Li
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-09-09

Review 7.  Cardiac Alterations in Patients with Familial Lipodystrophy.

Authors:  Minna Moreira Dias Romano; Paula Ananda Inês Chacon; Fernanda Naira Zambelli Ramalho; Maria Cristina Foss; André Schmidt
Journal:  Arq Bras Cardiol       Date:  2020-02       Impact factor: 2.000

8.  Congenital Generalized Lipoatrophy (Berardinelli-Seip Syndrome) Type 1: Description of Novel AGPAT2 Homozygous Variants Showing the Highly Heterogeneous Presentation of the Disease.

Authors:  Giovanni Ceccarini; Silvia Magno; Caterina Pelosini; Federica Ferrari; Maria Rita Sessa; Gaia Scabia; Margherita Maffei; Isabelle Jéru; Olivier Lascols; Corinne Vigouroux; Ferruccio Santini
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-14       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.